Coloplast (BMV:0QBO N) - Aandelenkoers, Nieuws & Analyse

0QBO N Overzicht aandelen

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Meer informatie

0QBO N fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	2/6
Dividenden	3/6

Beloningen

De winst zal naar verwachting met 10.99% per jaar groeien

De winst groeide het afgelopen jaar met 1.2%

Risicoanalyse

Aandelen zijn zeer illiquide

Heeft een hoog schuldenniveau

Coloplast A/S Concurrenten

Cooper Companies

NasdaqGS:COO

US$19.8b

Alcon

SWX:ALC

CHF 37.8b

HOYA

TSE:7741

JP¥7.0t

Align Technology

NasdaqGS:ALGN

US$16.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Coloplast
Historische aandelenkoersen
Huidige aandelenkoers	DKK 2,082.59
52 Week Hoogtepunt	DKK 2,427.29
52 Week Laag	DKK 2,082.59
Bèta	0.22
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	26.87%
Verandering sinds IPO	65.47%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0QBO N	MX Medical Equipment	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 0QBO N presteerde ten opzichte van de MX Medical Equipment.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 0QBO N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is 0QBO N's price volatile compared to industry and market?
0QBO N volatility
0QBO N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: 0QBO N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0QBO N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1954	14,973	Kristian Villumsen	www.coloplast.com

Coloplast A/S Samenvatting

Hoe verhouden de winst en inkomsten van Coloplast zich tot de beurswaarde?
0QBO N fundamentele statistieken
Marktkapitalisatie	Mex$499.55b
Inkomsten(TTM)	Mex$12.47b
Inkomsten(TTM)	Mex$62.55b

40.0x

Koers/Winstverhouding

8.0x

P/S-verhouding

Is 0QBO N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0QBO N resultatenrekening (TTM)
Inkomsten	DKK 24.07b
Kosten van inkomsten	DKK 7.68b
Brutowinst	DKK 16.39b
Overige uitgaven	DKK 11.59b
Inkomsten	DKK 4.80b

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

Aug 17, 2023

Winst per aandeel (EPS)	22.60
Brutomarge	68.09%
Nettowinstmarge	19.94%
Schuld/Eigen Vermogen Verhouding	295.4%

Hoe presteerde 0QBO N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.2%

Huidig dividendrendement

88%

Uitbetalingsratio

0QBO N Overzicht aandelen

Beloningen

Risicoanalyse

Coloplast A/S Concurrenten

NasdaqGS:COO

US$19.8b

SWX:ALC

CHF 37.8b

TSE:7741

JP¥7.0t

NasdaqGS:ALGN

US$16.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Coloplast A/S Samenvatting

40.0x

8.0x

Inkomsten en omzet

Dividenden

2.2%

88%